Bausch Health Companies Inc. (TSE:BHC - Free Report) - Analysts at Zacks Research decreased their Q3 2026 earnings estimates for Bausch Health Companies in a report issued on Wednesday, August 19th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.44 for the quarter, down from their prior estimate of $1.47. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2026 earnings at $1.61 EPS, Q2 2027 earnings at $1.27 EPS, Q3 2027 earnings at $1.49 EPS, Q4 2027 earnings at $1.41 EPS, FY2027 earnings at $5.33 EPS, Q1 2028 earnings at $0.91 EPS and Q2 2028 earnings at $1.19 EPS.
Bausch Health Companies (TSE:BHC - Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported C$1.79 earnings per share for the quarter. Bausch Health Companies had a negative net margin of 12.02% and a positive return on equity of 87.57%. The firm had revenue of C$4.05 billion for the quarter.
Separately, Jefferies Financial Group upgraded Bausch Health Companies to a "hold" rating in a research note on Wednesday, July 22nd. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has a consensus rating of "Hold".
View Our Latest Research Report on Bausch Health Companies
Bausch Health Companies Trading Down 0.7%
Shares of BHC stock opened at C$9.41 on Friday. The company has a quick ratio of 0.58, a current ratio of 1.44 and a debt-to-equity ratio of -1,173.29. The firm has a market cap of C$3.52 billion, a P/E ratio of -3.20, a PEG ratio of 0.21 and a beta of 0.96. The company has a 50 day moving average of C$7.49 and a 200-day moving average of C$7.56. Bausch Health Companies has a 12-month low of C$6.10 and a 12-month high of C$11.08.
Trending Headlines about Bausch Health Companies
Here are the key news stories impacting Bausch Health Companies this week:
- Positive Sentiment: Zacks raised its FY2026 EPS estimate to $5.88 from $5.54, above the current consensus estimate of $5.55. The firm also increased its FY2027 forecast to $5.33 from $5.06.
- Positive Sentiment: Several quarterly estimates were upgraded, including Q1 2027 EPS to $1.17 from $1.13, Q2 2027 EPS to $1.27 from $1.15, Q3 2027 EPS to $1.49 from $1.46, and Q4 2027 EPS to $1.41 from $1.32.
- Positive Sentiment: Zacks also raised its longer-dated estimates for Q1 2028 EPS to $0.91 from $0.81 and Q2 2028 EPS to $1.19 from $1.14, suggesting improved expectations for earnings in portions of 2027 and 2028.
- Neutral Sentiment: The revisions leave Zacks’ current full-year consensus reference at approximately $5.55 EPS, while the firm’s FY2027 estimate of $5.33 remains below that level.
- Negative Sentiment: Zacks lowered its Q3 2026 EPS forecast to $1.44 from $1.47 and reduced its Q4 2026 estimate to $1.61 from $1.62. It also trimmed FY2028 EPS to $4.22 from $4.26.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc NYSE: BHCTSX: BHC is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
